Premium
Topiramate in Lennox–Gastaut Syndrome: Open‐Label Treatment of Patients Completing a Randomized Controlled Trial
Author(s) -
Glauser Tracy A.,
Levisohn Paul M.,
Ritter Frank,
Sachdeo Rǎjesh C.
Publication year - 2000
Publication title -
epilepsia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.687
H-Index - 191
eISSN - 1528-1167
pISSN - 0013-9580
DOI - 10.1111/j.1528-1157.2000.tb02179.x
Subject(s) - lennox–gastaut syndrome , topiramate , medicine , dose , concomitant , placebo , randomized controlled trial , open label , randomization , anesthesia , epilepsy , surgery , psychiatry , alternative medicine , pathology
Summary: Purpose : The response to topiramate (TPM) as long‐term adjunctive therapy was evaluated in patients with Lennox‐Gastaut syndrome (LGS) in a long‐term, open‐label extension to a double‐blind, placebo‐controlled trial. Methods : In 97 patients with LGS (mean age, 11 years), dosages of TPM and concomitant antiepileptic drugs (AEDs) were adjusted to optimal clinical response (mean TPM dosage, 10 mg/kg/day). Results : For those patients who had completed 6 months of TPM therapy, drop attacks were reduced ges;50% in 55% of patients; 15% of patients had no drop attacks for ges;6 months at the last visit. After treatment up to 3 + years, 71% of patients who started open‐label TPM were continuing therapy at the last visit. Conclusions : During long‐term therapy, TPM is effective and well tolerated in controlling the treatment‐resistant drop attacks and seizures associated with LGS.